IQVIA DEFINITIONS (May 2021)
DOWNLOADED VIA
ANALYSIS):
ON IQVIA PORTAL FOR THE BELOW SECTIONS (EXCEPT
SALES DATA
Data Source(s) / Report Description / Definitions / Coverage / Updates / MIDAS Panel
Coverage / Disease Module: Medical Panel Coverage / Exchange Rates / Methodology
Data Source(s)
1. MIDAS Audited Value
The figures for the data source represent cash value sales derived from MIDAS data
based on sales calculated at manufacturer selling prices.
The data grid shows a aggregated total sales for the country, the top 20 products based
on latest sales and total others for all other products outside of the top 20. The sales for
each of the top 20 products and total others represents aggregated total from sales in
the specific country hub you are in.
2. MIDAS Audited Volume
The figures for the data source represent volume sales derived from MIDAS data.
The data grid shows a aggregated total sales for the country, the top 20 products based
on latest sales and total others for all other products outside of the top 20. The sales for
each of the top 20 products and total others represents aggregated total from sales in
the specific country hub you are in. The list of 20 products remain the same as MIDAS
Audited Value when the data source is changed to MIDAS Audited Volume.
•
•
•
•
Standard Units volume measurement represents the number of smallest common
form doses sold.
For example for a tablet form product, standard units will show the number of
tables sold.
For certain formulations the dose is defined by IMS according to the product
form.
Please note all though standard units are derived at a form level, data at a form
level is not available in the platform.
3. MIDAS Audited Kilogram
The figures for the data source represent chemical weight sales derived from MIDAS
data.
The data grid shows a aggregated total sales for the country, the top 20 products based
on latest sales and total others for all other products outside of the top 20. The sales for
each of the top 20 products and total others represents aggregated total from sale in the
specific country hub you are in. The list of 20 products remain the same as MIDAS
Audited Value when the data source is changed to MIDAS Audited Kilogram.
4. MIDAS Patient Day
The figures for the data source represent patient days sales derived from MIDAS data by
combining dividing MIDAS standard unit sales by average daily dose (AVDD). NB: The
patient days measure data is not available for oncology data.
5. Average Daily Dose
The average daily dose in standard units, based on MIDAS Prescribing Insights
summary data and other secondary research.
6. MIDAS Sales Level Implied Price per Standard Unit
The figures for the data source represent the implied price driven based on MIDAS
Audited MNF value and standard units.
Price per standard unit is only accessible to Forecast Link and AC Enhanced Module
subscribers.
However, it be calculated by running both MIDAS sales value and volume extracts and
calculating the factor between the two to derive the implied price.
For the below example, 80,239,584 / 50,725,161 = $0.625.
7. MIDAS Sales Level Implied Price per Patient Day
The figures for the data source represent the implied price driven based on MIDAS
Audited MNF value and patient days.
8. Company reported Sales Value
Company reported sales values show product sales aligned with published annual and
quarterly reported data for 160 companies.
9. Analyst Consensus Value
Analyst consensus provides a 7 year forecast based on a mean average of broker
forecasts produced by investment bank and security firm analysts.
Company reported/Analyst consensus volume provides a 5 year historical and 7 year
forecast which are based on SU driven in lockstep with company reported and analyst
consensus values respectively.
10. Company-reported Sales Level Implied Price per Standard Units
The figures for the data source represent the implied price driven based on company
reported sales value and standard units.
11. MIDAS Audited Value/OTC Value
The figures for the data source represent cash value sales derived from MIDAS and
OTCims data based on sales calculated at manufacturer selling prices.
The data grid shows a total for the molecular entity across the countries covered within
the platform, the top 20 products based on latest sales and total others for all other
products outside of the top 20. The sales for each of the top 20 products and total others
also represents global sales across the countries within the platform.
Bain does not subscribe to IQVIA’s OTC module.
12. MIDAS Audited Volume/OTC Volume
The figures for the data source represent volume sales derived from MIDAS and OTC
IMS data.
The data grid shows a total for the molecular entity across the countries covered within
the platform, the top 20 products based on latest sales (by value) and total others for all
other products outside of the top 20. The sales for each of the top 20 products and total
others also represents global sales across the countries within the platform. The list of
20 products remain the same as MIDAS Audited Value/OTC Value when the data source
is changed to MIDAS Audited Volume/OTC Volume.
Report Description
1. MIDAS Audited Value The figures for the data source represent cash value sales
derived from MIDAS data based on sales calculated at manufacturer selling prices. The
data grid shows a total for the country you are in, the top 20 products based on latest
calendar year sales and total others for all other products outside of the top 20. The
sales for each of the top 20 products and total others also represents total sales for the
country.
2. MIDAS Audited Volume The figures for the data source represent volume sales derived
from MIDAS data. The data grid shows a total for the country you are in, the top 20
products based on latest calendar year sales and total others for all other products
outside of the top 20. The sales for each of the top 20 products and total others also
represents total sales for the country. The list of 20 products remain the same as MIDAS
Audited value when the data source is changed to MIDAS Audited Volume.
3. MIDAS Audited Kilogram The figures for the data source represent chemical weight
sales derived from MIDAS data. The data grid shows a total for the country you are in,
the top 20 products based on latest calendar year sales and total others for all other
products outside of the top 20. The sales for each of the top 20 products and total others
also represents total sales for the country. The list of 20 products remain the same as
MIDAS Audited Value when the data source is changed to MIDAS Audited Kilogram.
4. MIDAS Patient Day The figures for the data source represent patient days sales derived
from MIDAS data by combining dividing MIDAS standard unit sales by average daily
dose (AVDD). This offers a dose-adjusted volume measure of sales that is directly
comparable across products.
5. Average Daily Dose The average daily dose in standard units, based on MIDAS
Prescribing Insights summary data and other secondary research. AVDD varies for each
product by route of administration, and where necessary, is also disease or region
specific.
6. MIDAS Sales Level Implied Price per Standard Unit The figures for the data source
represent the implied price driven based on MIDAS Audited MNF value and standard
units.
7. MIDAS Sales Level Implied Price per Patient Day The figures for the data source
represent the implied price driven based on MIDAS Audited MNF value and patient days.
8. Company reported sales Company reported sales values show product sales for the
country you are in and are derived from sales aligned with published annual and
quarterly reported data for 160 companies.
9. Analyst Consensus value forecasts Analyst consensus sales value show product
sales for the country you are in and is based on a mean average of broker forecasts
produced by investment bank and security firm analysts.
10. Company reported/Analyst Consensus Volume forecasts Company reported/Analyst
consensus volume show product sales for the country you are in and is based on SU
derived in lockstep with company reported value and analyst consensus values
respectively.
11. Company-reported Sales Level Implied Price per Standard Units The figures for the
data source represent the implied price for the country you are in, driven based on
company reported sales value and standard units.
Definitions
1. International Product Name (Brand Name)
For products on the market, IQVIA consolidates the various brand names used in
different countries. Usually this is the ‘commonly used’ name or the name from the
country of first launch. Products are consolidated under one name if 2 out of 3 of the
following match: product name, corporation, and active ingredient. When a product
cannot be grouped in this way with any other products internationally it is identified with
an "@" symbol along with the country it is available in.
In the case where a ‘generic name’ is used, an abbreviation of the owning company’s
name is added, where it is known. For drugs of this type consolidated under one name,
the 3 out of 3 of the following criteria must match: product name, corporation, and active
ingredient.
2. Pharmaceutical Molecule Name
The name of the molecular entity
3. Corporation
The Corporation column represents the corporations which have sales for the product
within MIDAS data. The primary corporation which is specified in the grid is the
corporation with the highest sales for the product in MIDAS data. If the corporation has a
+ sign followed by a number, for example +10, hovering over the +10 reveals a list of 10
other corporations which also have sales for this product in MIDAS data.
4. ATC
IMS use the hierarchical Anatomical Therapeutic Classification (ATC) standard. It is a
way of grouping, and therefore a way to look at, similar products. At its broadest level the
system classifies products according to the parts of the body that they are used to treat.
At the lower levels it uses therapeutic use, indication, mode of action, pharmacology etc.
to define sub groups. Classes consist of a description and/or code. Both are used
throughout this service.
Code Description
Level
A
Alimentary Tract and Metabolism
Level 1
A2 Antacids, Antiflatulents and Antipeptic Ulcerants Level 2
A2A Antacids, Antiflatulents, Carminatives
Level 3
A2A1 Plain Antacids
Level 4
The EphMRA (European Pharmaceutical Market Research Association) Classification
Committee originally prepared the Anatomical Therapeutic Classification Guidelines.
More information can be found at www.ephmra.org. The primary objective of the
Anatomical Therapeutic Classification is to satisfy the marketing needs of companies
who are engaged in researching the pharmaceutical industry. Products are mainly
classified according to their indications and use. Therefore it is possible to find the same
compound in several classes; e.g. ibuprofen can be classified in M1A (Anti-rheumatic),
N2B (Analgesic) and G2X (Other Gynaecological Products) if indicated for
gynaecological conditions only.
5. Disease
The Disease column represents the Disease area (according to the Analytics disease
taxonomy) or a specific ICD10 code
6. Primary / Specialty
Drugs in each ATC have been classified as specialty if they treat specific, complex chronic
diseases with four or more of the following attributes: Initiated only by a specialist, generally
not oral form, require special handling, unique distribution, high expense, warrants intensive
patient counselling, requires reimbursement assistance.
7. Channel
The split by channel is based on sales across all sales for each channel type. The list of
channel types is as follows: Retail Algeria, Argentina, Australia, Austria, Bangladesh,
Belgium, Brazil, Bulgaria, Canada, Central America, Chile, China, Colombia, Croatia, Czech
republic, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, French West Africa,
Germany (retail), Greece, Hungary, Indonesia (Retail, Drug), Ireland, Italy, Japan, Jordan,
Kazakhstan, Korea, Kuwait, Latvia, Lebanon, Lithuania, Luxembourg, Mexico, Morocco,
Netherlands (Xponent), New Zealand, Norway, Pakistan, Peru, Philippines, Poland, Portugal,
Puerto Rico, Romania, Russia (Retail+DLO), Saudi Arabia, Slovak Republic, Spain (retail),
Sri Lanka, Switzerland, Taiwan, Thailand, Tunisia, Turkey, United Arab Emirates, UK (SellIn), Uruguay (Retail + Mutuales), USA (Drugstore, Foodstore, Mail Service), Venezuela and
Vietnam. Hospital Australia, Austria, Belgium, Bulgaria, Canada, China, Croatia, Czech
republic, Finland, France, Germany, Hungary, Indonesia, Ireland, Italy (Hospital+DPC),
Japan, Kazakhstan (Non-retail), Korea (Hospital+Clinic), Lithuania, Malaysia, Netherlands
(Hospital IMS), New Zealand, Norway, Philippines, Poland, Portugal, Puerto Rico, Romania,
Russia, Singapore, Saudi Arabia (LPO), Slovak Republic, South Africa, Spain, Switzerland,
Taiwan, Thailand, Tunisia, Turkey, United Arab Emirates, UK, USA (Non-Fed Hospital, Misc,
Long Term Care, Home Health Care, HMO, Fed Facilities, Clinic) and Vietnam. Combined
Hong Kong, India (total sales), Malaysia, Serbia, Singapore, Slovenia, Sweden, South Africa.
8. Generic / Non-Generic
The generic product classification is based on the market segmentation generic product
classification derived from MIDAS which assigns each local product to one of six categories:
Biocomparable Products, Early Entry Generic Products, Non Generic products, Generic
Products, Other Products and Non Categorized products. This classification currently covers
the 33 countries outlined in coverage. Sales for all other countries are assigned to Non
categorized products category.
BIOCOMPARABLES – Products that have been approved through official biosimilar
approval pathways in countries where this process exists. In addition, products of the
same molecule, brand name and corporation in countries without official biosimilar
approval processes are also classified in this category.
GENERIC PRODUCTS – Products that fall within the IMS definition of a generic product
• i.e. Products that have never benefited from any form of protection, were launched
post-protection expiry of the original product and were subsequently launched products
to the original OR either company branded or unbranded products that are no longer
protected (early entry licensed generic products).
• NON-GENERIC PRODUCTS – Products that fall within the IMS definition of a nongeneric product
• i.e. Products that currently benefit from any form of protection, OR branded products
that have once but no longer benefit from some form of protection OR first launch
products (i.e. the product of that composition with the earliest launch date in that country)
that have never benefited from any form of protection, were launched post-protection
expiry of the original product
• OTHER PRODUCTS - Products that have never benefited from any form of protection
and were launched pre-protection expiry of the original product.
• NON CATEGORISED PRODUCTS - products for which Protection is coded as Under
Investigation, Unknown or Not Covered
9. Biologic / Non Biologic
Data is categorized at a molecule level and then aggregated up to the following
categories: Biologic product - If a product contains a Biologic molecule as the active
ingredient (or a number of Biologic molecules are active ingredients) and there are no
Non-Biologic molecules present as active ingredients then the product is defined as
Biologic Product. Non Biologic Product - A product that contains only Non-Biologic
molecule(s) as the active ingredient(s) is defined as a Non-Biologic Product. Bio/Non Bio
Combi product - A product that contains both a Biologic and a Non-Biologic molecule(s)
is defined a Bio/Non Bio Combi product. BIO-PRD Unknown - The category of BIO-PRD
Unknown occurs only when the composition of all packs of a product are unknown. In
such a case, with no known ingredients, the biologic status of the product's ingredients
cannot be determined. IMS uses the following defining characteristics to categorize a
biologic: Molecular structure - Biologic molecules are complex macromolecules, typically
with some form of polymer structure. Specific macromolecules included in this definition
are proteins, nucleic acids and carbohydrates. Molecular Identification - Biologic
molecules must be clearly identified. Any 'molecule' where the molecule name is
descriptive and the actual composition of the molecule is not identified (e.g. Vegetable
Extract) will not be classified as a biologic. Active Substance - Biologic molecules must
be, or are intended to be clearly defined active therapeutic ingredients in a product.
Regulatory - Biologic molecules must have undergone (or be undergoing) a regulatory
human clinical trial programme under the auspices of a national / regional regulatory
authority.
10. Change
The change column represents the value change from the earliest time period to the
latest time period.
11. Currency
The sales data is convertible into a number of different currencies from the drop down
list above the sales data grid. The sales are converted from each local currency for the
70+ countries in the Analytics Link universe to the currency selected from the drop down.
The currencies are supplied to IMS based on a quarterly average between the local and
selected currencies by Oanda. Analytics Link uses these quarterly average rates to
convert the sales into the selected currency and provides an aggregated total for the
calendar year or moving annual total. For Euros, Dollars and Pound Sterling, there is
also a constant exchange rate option which uses the last quarter in the time series to
reference the average exchange rate and then applies this rate to all previous periods.
The constant currency option are shown as LC US Dollars, LC Euros & LC Pound
Sterling within the currency drop down.
For a list of exchange rates, please see the last section of the 'user guide' available from
the 'Help' link at the top of the screen.
12. Standard Units
Standard Units volume measurement represents the number of smallest common form
doses sold. For example for a tablet form product, Standard Units will show the number
of tablets sold. For certain formulations the dose is defined by IMS according to the
product form. Please note although Standard Units volume is derived at a form level,
data at a form level is not available in the platform.
13. MIDAS Audited Kilogram
Kilogram measurement represents chemical weight of active ingredient (molecule) in the
product. Please note, kilogram values for all combination products (e.g. Seretide,
fluticasone + salmeterol) represent aggregated kilogram sales of all constituent
molecules (e.g. fluticasone + salmeterol combined).
14. Patient Days
Patient Days measurement represents sales derived from MIDAS data by combining
dividing MIDAS standard unit sales by average daily dose (AVDD). This offers a doseadjusted volume measure of sales that is directly comparable across products. NB: The
patient days measure data is not available for oncology data.
15. Company reported sales value
Company reported sales values provides a 10 year historical product sales for the global
brand and are derived from sales reported to the stock market by public listed
companies from the top 1200 companies available in the platform.
16. Analyst Consensus value forecasts
Analyst consensus provides a 7 year forecast value based on a mean average of broker
forecasts produced by investment bank and security firm analysts. A minimum of 3
broker reports published within the same quarter are used to create the consensus
forecast. Some of the brokers behind the analyst consensus forecasts include brokers
from: Bank am Bellevue, Barclays, Cantor Fitzgerald, Cowen & Co, Credit Suisse,
Deutsche Bank, Guggenheim, Jefferies, JP Morgan, Leerink Swann, Mitsubishi UFJ,
Morgan Stanley, Piper Jaffray, RBC Captial, SMBC Nikko, Societe Generale and
Wedbush. This is a representative list of brokers used, not exhaustive.
17. Company reported/Analyst consensus forecasts
Company reported/Analyst consensus volume provides a 5 year historical and 7 year
forecast which are based on SU driven in lockstep with company reported and analyst
consensus sales value respectively.
Coverage
1. Country specific MIDAS Audited Value, MIDAS Audited Volume, MIDAS Audited
Kilogram and MIDAS Audited Patient Day coverage
MIDAS Audited Value, MIDAS Audited Volume, MIDAS Audited Kilogram and MIDAS
Patient Day are based on an aggregated total from sales in the specific country hub you
are in.
2. Generic / Non-Generic coverage
Figures are global aggregated totals from the following countries covered by MIDAS market
segmentation coding: Algeria, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria,
Canada, Chile, China, Colombia, Czech Republic, Ecuador, Egypt, Finland, France,
Germany, Greece, Hungary, India, Indonesia, Ireland, Italy, Japan, Malaysia, Mexico,
Netherlands, New Zealand, Norway, Pakistan, Peru, Philippines, Poland, Portugal, Romania,
Russia, Saudi Arabia, Slovak Republic, Slovenia, South Africa, South Korea, Spain, Sweden,
Switzerland, Taiwan, Thailand, Turkey, UK, United Arab Emirates, Uruguay, USA, Venezuela
and Vietnam.
3. Company reported sales coverage
Company reported sales represent global sales across all countries.
4. Analyst Consensus value forecast coverage
Analyst Consensus forecasts represent global sales across all countries.
5. Analyst Consensus volume forecast coverage
Analyst Consensus forecasts represent global volume sales across all countries.
Updates
1. Sales Data
MIDAS Sales data is updated each quarter approximately 10-12 weeks after the period
end, or annually in April, depending on your subscription.
2. Company Information
Company-reported sales data, financials and other information is updated quarterly.
3. Analyst consensus
Analyst Consensus value and volume sales data updated quarterly.
PIPELINE DATA
Data Source(s) / Report Description / Definitions / Coverage / Updates / MIDAS Panel
Coverage / Disease Module: Medical Panel Coverage / Exchange Rates / Methodology
Data Source(s)
IMS LifeCycle R&D Focus
Report Description
The 3 widget view provides a view on all three pipeline widgets; Phase list, Phase count
and Bulls eye. Each of these widgets are expandable by clicking the maximise /minimize
button. The grid shows all active products in development for the current drug, company,
or therapy class.
Definitions
1. Pipeline Product Name
Identifies the pipeline product name of the product being developed.
2. Corporation
Identifies the corporation involved in the development of the drug. The number next to
the corporation reflects the number of other companies involved in the development of
that product (for that phase and for that indication), and mousing over this number
reveals a the full list of these company names.
3. Indication
A description of the likely medical use of a drug - using standard terms.
4. Development Stage
This refers to the phase of development reached by the drug anywhere in the world.
Phases can be as follows:
Discovery - These relate to drugs for which no lead compound has been identified and
pre-clinical evaluation has not yet begun. This will include all early stage collaborative
agreements, drug discovery agreements, target-based screening programs and
collaborations, gene discovery programs. The drugs will move to pre-clinical phase, once
a lead compound enters pre-clinical studies.
Preclinical - covers early research, as well as in vitro and in vivo studies. Drug design
technologies and delivery systems are also defined as preclinical.
Clinical - is a general term we use when the company refers to the drug as being in
clinical trials but they don't specify if it is in phase I, II or III. It has the same status as
phase I in terms of the search strategy.
Phase I - small-scale, early human studies, covering drug safety, pharmacokinetics and
dosage. Usually conducted in healthy volunteers, or, in the case of antitumor agents, in
terminal cancer patients.
Phase II - small-scale human studies, to evaluate safety and efficacy, and monitor sideeffects. Conducted in patients with the relevant disease or condition
Phase III - large scale efficacy studies, often blinded and placebo-controlled, used to
compile data for submission to regulatory bodies, e.g. FDA (USA), EMEA (Europe).
Pre-registration - submission for approval to regulatory authorities
Registered - approval for marketing by regulatory body.
Marketed - available on markets
Coverage
Global
Updates
1. R&D Focus Data
The R&D information is updated daily.
LAUNCH DATA
Data Source(s) / Report Description / Definitions / Coverage / Updates / MIDAS Panel
Coverage / Disease Module: Medical Panel Coverage / Exchange Rates / Methodology
Data Source(s)
All launch data is based on IMS MIDAS launch dates.
Report Description
The 3 widget view provides a view on all three launch widgets; Timeline, Timeline count
and sales by launch year. Each of these widgets are expandable by clicking the
maximise /minimize button. The grid shows launch dates by country for every product for
the current drug, company, country or therapy class.
Definitions
1. International Product Name
For products on the market, IQVIA consolidates the various brand names used in
different countries. Usually this is the ‘commonly used’ name or the name from the
country of first launch. Products are consolidated under one name if 2 out of 3 of the
following match: product name, corporation, and active ingredient. When a product
cannot be grouped in this way with any other products internationally it is identified with
an "@" symbol along with the country it is available in.
In the case where a ‘generic name’ is used, an abbreviation of the owning company’s
name is added, where it is known. For drugs of this type consolidated under one name,
the 3 out of 3 of the following criteria must match: product name, corporation, and active
ingredient.
2. Local Product Name
The local product column shows the product name as it appears on the pack in a specific
country. Products marked with a chevron ">>" indicates a parallel import
3. Country
The country covered by the report. Note that not all channels of distribution are covered
in all countries. Please see the channel to see which distribution channels by country are
covered.
4. Corporation
The Corporation column represents the corporations which have sales for the product
within MIDAS data. The primary corporation which is specified in the grid is the
corporation with the highest sales for the product in MIDAS data. If the corporation has a
+ sign followed by a number, for example +10, hovering over the +10 reveals a list of 10
other corporations which also have sales for this product in MIDAS data.
5. Local Manufacturer
A local manufacturer is the local operator responsible for the selling and marketing of a
product within that country.
6. Generic / Non Generic
The generic product classification is based on the market segmentation generic product
classification derived from MIDAS which assigns each local product to one of six
categories: Biocomparable Products, Early Entry Generic Products, Non Generic
products, Generic Products, Other Products and Non Categorized products. This
classification currently covers the 33 countries outlined in coverage. Sales for all other
countries are assigned to Non categorized products category.
7. Launch Date
Generally this is the month and year that the product first appeared in an IMS audit and
can vary from the marketing approval date due to various factors such a pre-stocking or
delayed launches. For very recent or very old launches the date may not yet have been
coded and has a past unknown launch date. A break down of what the launch date
indicates by country is as follows:
Country
ALGERIA
ARGENTINA
AUSTRALIA
AUSTRIA
BANGLADESH
BELGIUM
BRAZIL
BULGARIA
CANADA
CENTRAL
AMERICA
CHILE
CHINA
COLOMBIA
CROATIA
CZECH
REPUBLIC
DENMARK
DOMINICAN
REPUBLIC
ECUADOR
EGYPT
ESTONIA
FINLAND
FRANCE
FRENCH WEST
AFRICA
Date from which
Date of launch
sales first begin to
Other
by manufacturer
accumulate
√
√
√
Date of product licence grant
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
GERMANY
GREECE
HONG KONG
√
√
√
Date when the Ministry of
Welfare officially published
price of the product
HUNGARY
INDIA
INDONESIA
IRELAND
ITALY
JAPAN
JORDAN
KOREA
KUWAIT
LATVIA
LEBANON
LITHUANIA
LUXEMBOURG
MALAYSIA
MEXICO
MOROCCO
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
Date when the Pharmacy
Organization (KNMP) officially
issues the relevant code for a
product
NETHERLANDS
NEW ZEALAND
NORWAY
PAKISTAN
PERU
PHILIPPINES
POLAND
PORTUGAL
PUERTO RICO
ROMANIA
RUSSIAN
FEDERATION
SAUDI ARABIA
SINGAPORE
SLOVAK
REPUBLIC
SLOVENIA
SOUTH AFRICA
SPAIN
SRI LANKA
SWEDEN
SWITZERLAND
TAIWAN
THAILAND
TUNISIA
TURKEY
UAE
UK
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
URUGUAY
USA
VENEZUELA
VIETNAM
√
√
√
√
Coverage
1. MIDAS Audited Value, Volume, Kilogram and Patient Day coverage
Figures are global aggregated totals from the following countries: Algeria, Argentina,
Australia, Austria, Bangladesh, Belarus, Belgium, Bosnia-Herzegovina, Brazil, Bulgaria,
Canada, Central America, Chile, China, Colombia, Croatia, Czech Republic, Dominican
Republic, Ecuador, Egypt, Estonia, Finland, France, French West Africa, Germany,
Greece, Hong Kong, Hungary, India, Indonesia, Ireland, Italy, Japan, Jordan,
Kazakhstan, Kuwait, Latvia, Lebanon, Lithuania, Luxembourg, Malaysia, Mexico,
Morocco, Netherlands, New Zealand, Norway, Pakistan, Peru, Philippines, Poland,
Portugal, Puerto Rico, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovak
Republic, Slovenia, South Africa, South Korea, Spain, Sri Lanka, Sweden, Switzerland,
Taiwan, Thailand, Tunisia, Turkey, UK, United Arab Emirates, Uruguay, USA and
Vietnam.
Updates
1. Launch Data
Launch data is updated each quarter approximately 10-12 weeks after the period end or
annually in April, depending on your subscription.
PROTECTION DATA
Data Source(s) / Report Description / Definitions / Coverage / Updates / MIDAS Panel
Coverage / Disease Module: Medical Panel Coverage / Exchange Rates / Methodology
Data Source(s)
All protection data is based on IMS MIDAS loss of protection dates.
Report Description
The 3 widget view provides a view on all three protection widgets; Timeline, Timeline
count and sales by loss of protection year. Each of these widgets are expandable by
clicking the maximise /minimize button. The grid shows loss of protection dates by
country for every product for the current drug, company, country or therapy class.
Definitions
1. International Product Name
For products on the market, IQVIA consolidates the various brand names used in
different countries. Usually this is the ‘commonly used’ name or the name from the
country of first launch. Products are consolidated under one name if 2 out of 3 of the
following match: product name, corporation, and active ingredient. When a product
cannot be grouped in this way with any other products internationally it is identified with
an "@" symbol along with the country it is available in.
In the case where a ‘generic name’ is used, an abbreviation of the owning company’s
name is added, where it is known. For drugs of this type consolidated under one name,
the 3 out of 3 of the following criteria must match: product name, corporation, and active
ingredient.
2. Local Product Name
The local product column shows the product name as it appears on the pack in a specific
country. Products marked with a chevron ">>" indicates a parallel import
3. Corporation
The Corporation column represents the corporations which have sales for the product
within MIDAS data. The primary corporation which is specified in the grid is the
corporation with the highest sales for the product in MIDAS data. If the corporation has a
+ sign followed by a number, for example +10, hovering over the +10 reveals a list of 10
other corporations which also have sales for this product in MIDAS data.
4. Local Manufacturer
A local manufacturer is the local operator responsible for the selling and marketing of a
product within that country.
5. ATC
IMS use the hierarchical Anatomical Therapeutic Classification (ATC) standard. It is a
way of grouping, and therefore a way to look at, similar products. At its broadest level the
system classifies products according to the parts of the body that they are used to treat.
At the lower levels it uses therapeutic use, indication, mode of action, pharmacology etc.
to define sub groups. Classes consist of a description and/or code. Both are used
throughout this service.
Code Description
Level
A
Alimentary Tract and Metabolism
Level 1
A2 Antacids, Antiflatulents and Antipeptic Ulcerants Level 2
A2A Antacids, Antiflatulents, Carminatives
Level 3
A2A1 Plain Antacids
Level 4
The EphMRA (European Pharmaceutical Market Research Association) Classification
Committee originally prepared the Anatomical Therapeutic Classification Guidelines.
More information can be found at www.ephmra.org. The primary objective of the
Anatomical Therapeutic Classification is to satisfy the marketing needs of companies
who are engaged in researching the pharmaceutical industry. Products are mainly
classified according to their indications and use. Therefore it is possible to find the same
compound in several classes; e.g. ibuprofen can be classified in M1A (Anti-rheumatic),
N2B (Analgesic) and G2X (Other Gynaecological Products) if indicated for
gynaecological conditions only.
6. Biologic / Non Biologic
Data is categorized at a molecule level and then aggregated up to the following
categories: Biologic product - If a product contains a Biologic molecule as the active
ingredient (or a number of Biologic molecules are active ingredients) and there are no
Non-Biologic molecules present as active ingredients then the product is defined as
Biologic Product. Non Biologic Product - A product that contains only Non-Biologic
molecule(s) as the active ingredient(s) is defined as a Non-Biologic Product. Bio/Non Bio
Combi product - A product that contains both a Biologic and a Non-Biologic molecule(s)
is defined a Bio/Non Bio Combi product. BIO-PRD Unknown - The category of BIO-PRD
Unknown occurs only when the composition of all packs of a product are unknown. In
such a case, with no known ingredients, the biologic status of the product's ingredients
cannot be determined. IMS uses the following defining characteristics to categorize a
biologic: Molecular structure - Biologic molecules are complex macromolecules, typically
with some form of polymer structure. Specific macromolecules included in this definition
are proteins, nucleic acids and carbohydrates. Molecular Identification - Biologic
molecules must be clearly identified. Any 'molecule' where the molecule name is
descriptive and the actual composition of the molecule is not identified (e.g. Vegetable
Extract) will not be classified as a biologic. Active Substance - Biologic molecules must
be, or are intended to be clearly defined active therapeutic ingredients in a product.
Regulatory - Biologic molecules must have undergone (or be undergoing) a regulatory
human clinical trial programme under the auspices of a national / regional regulatory
authority.
7. Loss of Protection Date
Provides IMS estimate of when the product will no longer be protected from generic
competition. The following consideration are taken in determining the expiry date:
Patents, SPCs (Supplementary Protection Certificate), CPCs (Complementary
Protection Certificate), Data exclusivity, Marketing exclusivity, Delivery device patents,
composition patents, Orphan drug status, Paediatric exclusivity, Paediatric patent
extensions & known on-going litigation.
Protection expiry date unknown and past: -Original and Licensed Brands with early
launch dates, launched in countries where patent protection was known to exist but little
or no patent information is available, are assumed to have been protected at the time of
launch if it can be demonstrated that patents existed in a similar market at that time. In
this situation the product would be coded with a protection expiry date of unknown past.
Protection expiry date unknown and future: -Products that are known to be currently
protected but for which the protection expiry cannot be accurately predicted. For
example, recombinant or other high technology products where complexities in the
manufacturing and approval processes add an extra deterrent to competitors on top of
patents, exclusivity etc. In this situation a product would be coded with a protection
expiry date of Unknown future.
Coverage
1. Protection Coverage
Dates & figures are from the following countries covered by MIDAS market segmentation
coding: Algeria, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile,
China, Colombia, Czech Republic, Ecuador, Egypt, Finland, France, Germany, Greece,
Hungary, India, Indonesia, Ireland, Italy, Japan, Malaysia, Mexico, Netherlands, New
Zealand, Norway, Pakistan, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi
Arabia, Slovak Republic, Slovenia, South Africa, South Korea, Spain, Sweden,
Switzerland, Taiwan, Thailand, Turkey, UK, United Arab Emirates, Uruguay, USA,
Venezuela and Vietnam.
Updates
1. Protection Data
Protection data is updated each quarter approximately 10-12 weeks after the period end
or annually in April, depending on your subscription.
DEALS DATA
Data Source(s) / Report Description / Definitions / Coverage / Updates / MIDAS Panel
Coverage / Disease Module: Medical Panel Coverage / Exchange Rates / Methodology
Data Source(s)
IMS PharmaDeals
Report Description
This sub tabs shows all merger & acquisition deals as well as any divestment deals
related to the current drug, company, country or therapy class.
Definitions
1. Acquiring Company
Identifies the company acquiring the target company
2. Target company
Identifies the company targeted for acquisition
3. Product
Identifies any specific product in the target companies portfolio which is linked to the
drug, therapy, company or country hub page you are on.
4. Product Description
Provides a description of the product type from the following categories: Biomarkers Any
transaction relating to a naturally occurring molecule, gene or characteristic by which a
particular pathological or physiological process or disease can be identified. Companion
Diagnostic Any transaction relating to a diagnostic that provides information that is
essential for the safe and effective use of a corresponding therapeutic product. Includes
diagnostics to identify patients who are most likely to benefit from a particular therapeutic
product, diagnostics to identify patients likely to be at increased risk for serious adverse
reactions as a result of treatment with a particular therapeutic product and diagnostics to
monitor response to treatment for the purpose of adjusting treatment (e.g. schedule,
dose) to achieve improved safety or effectiveness. Diagnostic Any transaction relating to
products or technologies involving the determination of cause or confirmation of an
illness. Drug Delivery Technology Any transaction relating to products or technologies
involved in the delivery of drugs to the body. Includes gene delivery. Evidence-based
Research Any transaction relating to evidence-based research to inform pharmaceutical
R&D and/or improve the treatment of disease. Includes comparative effectiveness
studies. Manufacturing Technology Any transaction relating to technologies involved in
the manufacturing of therapeutics, diagnostics, medical devices or vaccines. Medical
Device Any transaction relating to products or technologies that are used as a device
within the medical industry. Includes biomaterials, lab equipment, monitoring devices,
surgical devices etc. OTC Any transaction relating to products or technologies that are
sold over the counter. Protein engineering Any transaction relating to products or
technologies for the engineering of the structure of proteins so as to produce desired
properties, or the synthesis of proteins with particular structures. Includes antibody
fragments, bispecific antibodies, antibody-drug conjugates and engineered proteins with
novel amino acids. Research Technologies Any transaction relating to technologies
involved in research. Sub classified, including for cell lines, assay detection, DNA,
proteomics and bioprocessing. Software/ Bioinformatics Any transaction relating to
products or technologies that involves the use of computers in solving information
problems in the area of life sciences. It mainly involves the creation of electronic
databases of genomes and protein sequences, and techniques such as the threedimensional modelling of biomolecules and biological systems. Includes in silico
operations. Therapeutic Biological: Any transaction relating to products or technologies
made from a living organism or its products and is used in the prevention, diagnosis or
treatment of cancer and other diseases. Sub-classified, including antibodies, cell
therapy, stem cells, hormones, nucleotide-based and peptides. Gene Therapy: Includes
all aspects of gene therapy and any research relating to the structure or function of
specific genes. Generic: Generic versions of patent-expired medicines. These may or
may not have their own brand names. Natural Product: Any transaction relating to
products or technologies involving compounds that occur naturally in living organisms.
Includes extracts. Radiopharmaceuticals (Therapeutic): Any transaction relating to
therapeutic products or technologies that involve radioactivity. Small Molecule: Any small
molecule, i.e. a non-polymeric bioactive molecule that is not a peptide/protein, DNA/RNA
or complex carbohydrate. Includes synthetic or foreign chemicals (xenobiotics) and
vitamins and minerals. Vaccine Includes therapeutic and prophylactic vaccines, and
vaccine and immunotherapeutic adjuvants.
5. Deal Title
Title of the deal provides a brief description of the deal.
6. Total Deal Value (US$M)
The dollar value of the deal.
7. Deal Number
The deal number in the PharmaDeals database.
Coverage
Global
Updates
1. PharmaDeals
This is updated weekly.
FAQs
What can we get the latest year data e.g. 2020?
• According to IQVIA – latest year data will provisionally be available in late March
• From our GC IS healthcare expert: April – May 2021 would be more possible
according to previous year’s timeline
Are we able to get quarterly data for IQVIA?
• No, data is annual only
• Bain only subscribes to annual data – quarterly will have to be a separate ad hoc
purchase.
Do we have full access to the Oncology module?
• The country-level data is limited in the Oncology module. In the Oncology module
we can see total tumor-sales split by country, but not drug x tumor x country sales
splits.
•
There is the Enhanced Oncology Module that enriches the data available from the
standard Oncology Module that offers country-level data across all dimensions in
Analytics Link and in the Query Builder. Bain does not subscribe to this enhanced
module.
Can we get older data (more than 5 years)?
• IQVIA will not sell to Bainas they consider us their competitors
• Case teams can purchase through clients if required
How do I calculate Sales Level Implied Price per Standard Unit?
• You can calculate this by running both value and volume extracts and calculating the
factor between the two to derive the implied price.
•
Sales Level Implied Price per Standard Unit = Value / Volume
How can we determine the size of the biosimilars market?
In the Query Builder, we can use the below segments:
Query Builder Segments
Country
China
Biologic / Non-Biologic BIOLOGIC PRODUCTS
BIOCOMPARABLE PRODUCTS, EARLY ENTRY GENERIC PRODUCTS,
Generic / Non-Generic
GENERIC PRODUCTS
How does the order of the level in Query Builder affect the output?
In Query Builder the items that are displayed are based on the top 20 visible items based on
the preceding layers.
List 1:
Therapy(ATC1)
Therapy(ATC2)
Pharmaceutical Molecule Name
International Product Name
Corporation
List 2:
Therapy(ATC2)
Therapy(ATC3)
Pharmaceutical Molecule Name
International Product Name
Corporation
In List 1, for pharmaceutical molecule name, you will see the top 20 pharmaceutical
molecule names for each ATC2 code.
In List 2, you will see the top 20 pharmaceutical molecule names for each ATC3 code.
Because ATC3 is more granular than ATC2, that means there are more pharmaceutical
molecule names visible in report 2, and in turn – in the fifth level of the report – more
companies visible.
However, many items are displayed, the rows (e.g. companies) that are not listed individually
have their sales reported under ‘other’ so the totals still match.
What is the difference between Euro vs LC Euro or US Dollars vs LC US Dollars in the
Query Builder?
• LC Euro or LC US Dollars is based on a constant exchange rate e.g. 2020 exchange
rate used on 2019 to 2020 data
• Euro or US Dollars is based on the exchange rate of that particular year e.g. 2016
will use the exchange rate of 2016, 2017 will use the exchange rate of 2017
TO TAKE NOTE
•
IQVIA data is manufacturer selling price collected from a pharmacy and hospital
audit. This data does not match company net sales and does not take into account
discounts.
•
We only have 5 years of historic IQVIA data. We have analyst consensus
forecasts based on net sales but they do not match the historic data.
•
We only have the channel split for pharmacy and hospital. Online data is not
covered and would need to be purchased.
•
The data covers Prescription (Rx) and OTC but not all OTC.
o We do not have a split for Rx/OTC. Could be maybe 70% Rx and 30% OTC –
but it varies by category.
o Bain had a trial to their OTC module in 2019 but we didn’t think their OTC
data was very good
•
We only have brand level data and would need to purchase SKU level data.